Recent studies on retatrutide, a dual stimulant for glucagon-like peptide-1 and gastric inhibitory polypeptide, indicate promising findings in managing excess body fat and type 2 glucose intolerance. Preliminary data from clinical assessments point to considerable reductions in body weight and im